2016 AMREP Public Health Research Early-Career Researcher Best Paper Award

Prize: Prize (including medals and awards)


Public Health Category

Paper: Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study

Journal: The Lancet Infectious Diseases [IF: 22.433]

Summary: Australia is the first country to implement the national human papillomavirus (HPV) vaccination programme (covers types 6/11/16/18) for females and we have previously described dramatic falls in genital warts (types 6/11). But until I published this paper, there was no data on what was happening to the other two HPV types (16/18) covered in the vaccine. HPV 16/18 are very important because they are types that cause most cases of cervical cancer. The study looked over 10 years; 3 years before and 7 years after the HPV vaccination programme. For the first time we showed a near elimination of all vaccine preventable types (6/11/16/18) in young Australian women aged ≤25. This means that at current levels of vaccination (~73%) are sufficient for the almost complete eradication of the four vaccine-preventable types from the Australian population which means the HPV vaccine will result in dramatic falls in genital cancer in women.
Degree of recognitionLocal
Granting OrganisationsAlfred Medical Research and Education Precinct (AMREP)


  • Award
  • Publication
  • early career
  • research
  • HPV
  • Human papillomavirus
  • vaccination
  • program
  • public health
  • prevention